QPPV.COM KNOWLEDGE ASSESSMENT

Denecimig (Frehemgo): From Bispecific FVIII Mimic to Next-Generation Haemophilia A Pharmacovigilance

Test your understanding of the concepts covered by Denecimig (Frehemgo): From Bispecific FVIII Mimic to Next-Generation Haemophilia A Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of variables would best support interpretation of denecimig safety events across a diverse treated population?

Age, inhibitor status, disease severity, dosing interval, prior therapy, adherence and relevant laboratory findings. Country and product name alone. Bleeding history alone, because other characteristics do not affect interpretation. The number of pens dispensed, without information on actual administration.

Question 2 of 10 A patient develops a serious event shortly after switching from emicizumab to denecimig. Which information is especially important for reconstructing exposure?

Only the date the event was reported to the company. The prior product, its last dose, the interval between treatments and the reason for switching. Only the patient's current denecimig dose, without previous treatment details. The patient's preferred injection site and no other treatment history.

Question 3 of 10 Why does the article recommend continued immunogenicity surveillance even though denecimig is fully human?

Fully human antibodies are expected to cause neutralising antibodies in most patients. Human sequence does not eliminate the possibility of anti-drug antibodies affecting exposure, activity or clinical response. Immunogenicity testing is needed only to confirm that the patient has FVIII inhibitors. The article reports that all participants developed anti-denecimig antibodies.

Question 4 of 10 Why should paediatric denecimig cases be analysed with age and developmental context preserved?

Children cannot experience the same types of adverse events as adults. Growth, changing weight, caregiver administration and longer cumulative exposure may affect treatment context and interpretation. Paediatric exposure is too short to contribute to long-term safety assessment. Age is relevant only when the child has FVIII inhibitors.

Question 5 of 10 How should detection of anti-denecimig antibodies be interpreted in an individual case?

As definitive treatment failure, regardless of clinical response or antibody characteristics. In relation to assay findings, persistence, titre, neutralising capacity, exposure and clinical outcomes. As proof that the patient has developed FVIII inhibitors. As clinically irrelevant whenever the antibody is fully human.

Question 6 of 10 How should the October 2026 U.S. BLA review delay be described based on the information in the article?

As evidence that FDA identified deficiencies in clinical safety data. As a delay associated with manufacturing-facility remediation, with no reported clinical efficacy or safety data deficiency identified by FDA. As a rejection of the BLA because of an unacceptable thrombotic risk. As confirmation that denecimig cannot be manufactured to the required quality.

Question 7 of 10 A patient receiving monthly denecimig reports a treated breakthrough bleed. Which initial pharmacovigilance approach is most informative?

Classify the event as treatment failure based on the bleed alone. Assume the bleed is expected in haemophilia and close the case. Reconstruct the dose schedule, last administration, adherence, bleed details, treatment given and inhibitor status. Assess only the patient's FVIII activity and disregard administration history.

Question 8 of 10 Which description best captures how denecimig supports coagulation?

It replaces deficient FVIII by supplying a functional FVIII protein. It bridges FIXa and FX on activated platelet surfaces to facilitate FX activation. It reduces natural anticoagulant activity to increase thrombin generation. It directly converts FX into activated FX without engaging FIXa.

Question 9 of 10 Why can denecimig provide prophylaxis to patients who have developed FVIII inhibitors?

Its haemostatic action does not depend on FVIII remaining functionally available. It removes FVIII inhibitors from the circulation before they can affect treatment. It converts inhibitors into non-neutralising antibodies. It increases the patient's production of endogenous FVIII.

Question 10 of 10 What is the most appropriate role for QPPV oversight of denecimig safety?

Apply the same monitoring framework used for FVIII replacement without considering denecimig's mechanism. Ensure surveillance and governance reflect its coagulation mechanism and capture bleeding, thrombosis, immunogenicity, switching, administration and relevant context. Focus exclusively on laboratory markers because clinical events are too nonspecific. Delegate all safety interpretation to product-quality processes because the medicine uses a pre-filled pen.

QPPV.com

Denecimig (Frehemgo): From Bispecific FVIII Mimic to Next-Generation Haemophilia A Pharmacovigilance

Cookie Settings